Vyndamax, a new drug for transthyretin amyloid cardiomyopathy (ATTR-CM), is now available for prescription at general hospitals.

According to industry sources, Pfizer Korea’s ATTR-CM drug, 'Vyndamax (tafamidis 61mg),' passed the review of drug committees (DCs) at various medical institutions including Samsung Medical Center, Seoul Asan Medical Center, Hanyang University Medical Center, etc.

However still, the landing may not directly translate to active prescriptions, as Vyndamax is being prescribed to certain patients without reimbursement.

After the company failed to receive designation as an essential drug earlier this year, the company had applied for reimbur